Four Natural Compounds That Target Distinct Aging Pathways May Work Best Together

As the global population over 60 approaches 2.1 billion by 2050, strategies that target the biological mechanisms of aging—rather than individual diseases—are gaining urgency. This 2026 narrative review in Nutrients synthesizes evidence for four natural bioactive compounds selected specifically because they address mechanistically distinct, largely non-overlapping hallmarks of aging, making them rational candidates for combined functional food formulations.

Spermidine, a polyamine abundant in wheat germ (~337 mg/kg), natto, and aged cheeses, induces autophagy primarily by inhibiting the acetyltransferase EP300, derepressing ATG proteins (ATG5, ATG7, ATG12, LC3) independently of mTORC1. It also activates AMPK and SIRT1, suppresses the NLRP3 inflammasome, and modulates eIF5A hypusination to support mitochondrial respiratory complex synthesis. In the 20-year Bruneck Study cohort (n=829), higher dietary spermidine intake was associated with all-cause mortality rates falling from 40.5 to 15.1 deaths per 1,000 person-years across intake tertiles. The SmartAge phase IIb RCT (n=100, 12 months, 0.9 mg/day) did not meet its primary cognitive endpoint, likely reflecting doses far below habitual dietary exposure (8–12 mg/day).

Fisetin, a flavonol richest in strawberries (~160 mg/kg), acts as a senolytic by inhibiting the PI3K/AKT pro-survival axis and Bcl-2/Bcl-xL anti-apoptotic proteins in senescent cells, selectively lowering their apoptotic threshold. Its principal translational challenge is poor bioavailability—plasma concentrations from food are in the low nanomolar range, well below the micromolar concentrations required for senolysis in preclinical models—motivating intermittent high-dose supplementation and advanced delivery strategies.

Berberine, an isoquinoline alkaloid from Berberis species, activates AMPK to correct metabolic dysfunction and achieves unusually high intraluminal gut concentrations due to poor systemic absorption, enabling direct reshaping of gut microbiota composition. It carries the most extensive clinical dataset of the four compounds, with evidence across metabolic syndrome, type 2 diabetes, and dyslipidemia endpoints.

Urolithin A is a postbiotic produced by gut microbiota from ellagitannins in pomegranates and walnuts, inducing mitophagy via the PINK1/Parkin pathway to clear dysfunctional mitochondria. Because its production depends on microbiome composition, interindividual variability in urolithin A production is high, and supplementation with the compound directly bypasses this bottleneck. Multiple registered human clinical trials are ongoing.

The review's core argument is that together these four compounds address autophagy, senolysis, metabolic regulation, and mitochondrial quality control—four distinct but interconnected hallmarks—suggesting that a combined functional food formulation could provide broader anti-aging coverage than any single compound. The authors acknowledge no dedicated multi-compound co-administration trial currently exists, and they call for such studies as the field's most pressing next step. Bioavailability optimization, regulatory classification of functional foods versus supplements, and long-term safety data remain outstanding challenges for all four compounds.